Development of Elvitegravir Resistance and Linkage of Integrase Inhibitor Mutations with Protease and Reverse Transcriptase Resistance Mutations

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2012 Jul 21

PMID 22815755

Citations 22

Authors

Mark A Winters

Robert M Lloyd Jr

Robert W Shafer

Michael J Kozal

Michael D Miller

Mark Holodniy

Affiliations

Soon will be listed here.

Abstract

Failure of antiretroviral regimens containing elvitegravir (EVG) and raltegravir (RAL) can result in the appearance of integrase inhibitor (INI) drug-resistance mutations (DRMs). While several INI DRMs have been identified, the evolution of EVG DRMs and the linkage of these DRMs with protease inhibitor (PI) and reverse transcriptase inhibitor (RTI) DRMs have not been studied at the clonal level. We examined the development of INI DRMs in 10 patients failing EVG-containing regimens over time, and the linkage of INI DRMs with PI and RTI DRMs in these patients plus 6 RAL-treated patients. A one-step RT-nested PCR protocol was used to generate a 2.7 kB amplicon that included the PR, RT, and IN coding region, and standard cloning and sequencing techniques were used to determine DRMs in 1,277 clones (mean 21 clones per time point). Results showed all patients had multiple PI, NRTI, and/or NNRTI DRMs at baseline, but no primary INI DRM. EVG-treated patients developed from 2 to 6 strains with different primary INI DRMs as early as 2 weeks after initiation of treatment, predominantly as single mutations. The prevalence of these strains fluctuated and new strains, and/or strains with new combinations of INI DRMs, developed over time. Final failure samples (weeks 14 to 48) typically showed a dominant strain with multiple mutations or N155H alone. Single N155H or multiple mutations were also observed in RAL-treated patients at virologic failure. All patient strains showed evidence of INI DRM co-located with single or multiple PI and/or RTI DRMs on the same viral strand. Our study shows that EVG treatment can select for a number of distinct INI-resistant strains whose prevalence fluctuates over time. Continued appearance of new INI DRMs after initial INI failure suggests a potent, highly dynamic selection of INI resistant strains that is unaffected by co-location with PI and RTI DRMs.

Citing Articles

Forgiveness of INSTI-Containing Regimens at Drug Concentrations Simulating Variable Adherence .

Acosta R, DAntoni M, Mulato A, Yant S, Cihlar T, White K Antimicrob Agents Chemother. 2022; 66(5):e0203821.

PMID: 35389236 PMC: 9112893. DOI: 10.1128/aac.02038-21.

Why the HIV Reservoir Never Runs Dry: Clonal Expansion and the Characteristics of HIV-Infected Cells Challenge Strategies to Cure and Control HIV Infection.

Lau C, Adan M, Maldarelli F Viruses. 2021; 13(12).

PMID: 34960781 PMC: 8708047. DOI: 10.3390/v13122512.

Integrase Inhibitor Resistance Mechanisms and Structural Characteristics in Antiretroviral Therapy-Experienced, Integrase Inhibitor-Naive Adults with HIV-1 Infection Treated with Dolutegravir plus Two Nucleoside Reverse Transcriptase Inhibitors in....

Underwood M, Horton J, Nangle K, Hopking J, Smith K, Aboud M Antimicrob Agents Chemother. 2021; 66(1):e0164321.

PMID: 34694877 PMC: 8765460. DOI: 10.1128/AAC.01643-21.

Coevolved Multidrug-Resistant HIV-1 Protease and Reverse Transcriptase Influences Integrase Drug Susceptibility and Replication Fitness.

Martin S, Cane P, Pillay D, Mbisa J Pathogens. 2021; 10(9).

PMID: 34578103 PMC: 8470981. DOI: 10.3390/pathogens10091070.

Integrase Strand Transfer Inhibitors Are Effective Anti-HIV Drugs.

Smith S, Zhao X, Oliveira Passos D, Lyumkis D, Burke Jr T, Hughes S Viruses. 2021; 13(2).

PMID: 33572956 PMC: 7912079. DOI: 10.3390/v13020205.

References

Varghese V, Liu T, Rhee S, Libiran P, Trevino C, Fessel W . HIV-1 integrase sequence variability in antiretroviral naïve patients and in triple-class experienced patients subsequently treated with raltegravir. AIDS Res Hum Retroviruses. 2010; 26(12):1323-6. PMC: 2996813. DOI: 10.1089/aid.2010.0123. View

Molla A, Korneyeva M, Gao Q, Vasavanonda S, Schipper P, Mo H . Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat Med. 1996; 2(7):760-6. DOI: 10.1038/nm0796-760. View

Meyerhans A, Vartanian J, Wain-Hobson S . DNA recombination during PCR. Nucleic Acids Res. 1990; 18(7):1687-91. PMC: 330584. DOI: 10.1093/nar/18.7.1687. View

Baldanti F, Paolucci S, Gulminetti R, Brandolini M, Barbarini G, Maserati R . Early emergence of raltegravir resistance mutations in patients receiving HAART salvage regimens. J Med Virol. 2009; 82(1):116-22. DOI: 10.1002/jmv.21651. View

Soriano V, de Mendoza C . Genetic mechanisms of resistance to protease inhibitors and entry inhibitors. HIV Clin Trials. 2002; 3(3):249-57. DOI: 10.1310/hct.2002.3.3.009. View

Rodenburg C, Li Y, Trask S, Chen Y, Decker J, Robertson D . Near full-length clones and reference sequences for subtype C isolates of HIV type 1 from three different continents. AIDS Res Hum Retroviruses. 2001; 17(2):161-8. DOI: 10.1089/08892220150217247. View

Liu J, Miller M, Danovich R, Vandergrift N, Cai F, Hicks C . Analysis of low-frequency mutations associated with drug resistance to raltegravir before antiretroviral treatment. Antimicrob Agents Chemother. 2010; 55(3):1114-9. PMC: 3067114. DOI: 10.1128/AAC.01492-10. View

Canducci F, Sampaolo M, Marinozzi M, Boeri E, Spagnuolo V, Galli A . Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies. AIDS. 2009; 23(4):455-60. DOI: 10.1097/QAD.0b013e328323da60. View

Vandenbroucke I, Van Eygen V, Rondelez E, Vermeiren H, Van Baelen K, Stuyver L . Minor Variant Detection at Different Template Concentrations in HIV-1 Phenotypic and Genotypic Tropism Testing. Open Virol J. 2009; 2:8-14. PMC: 2678814. DOI: 10.2174/1874357900802010008. View

10.

Zolopa A, Berger D, Lampiris H, Zhong L, Chuck S, Enejosa J . Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV Type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial. J Infect Dis. 2010; 201(6):814-22. DOI: 10.1086/650698. View

11.

Malet I, Delelis O, Soulie C, Wirden M, Tchertanov L, Mottaz P . Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients. J Antimicrob Chemother. 2009; 63(4):795-804. DOI: 10.1093/jac/dkp014. View

12.

Ingale K, Bhatia M . HIV-1 integrase inhibitors: a review of their chemical development. Antivir Chem Chemother. 2011; 22(3):95-105. DOI: 10.3851/IMP1740. View

13.

Steigbigel R, Cooper D, Teppler H, Eron J, Gatell J, Kumar P . Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials. Clin Infect Dis. 2010; 50(4):605-12. PMC: 6076431. DOI: 10.1086/650002. View

14.

Molina J, LaMarca A, Andrade-Villanueva J, Clotet B, Clumeck N, Liu Y . Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study. Lancet Infect Dis. 2011; 12(1):27-35. DOI: 10.1016/S1473-3099(11)70249-3. View

15.

Hatano H, Lampiris H, Fransen S, Gupta S, Huang W, Hoh R . Evolution of integrase resistance during failure of integrase inhibitor-based antiretroviral therapy. J Acquir Immune Defic Syndr. 2010; 54(4):389-93. PMC: 2890029. DOI: 10.1097/QAI.0b013e3181c42ea4. View

16.

Hu Z, Kuritzkes D . Effect of raltegravir resistance mutations in HIV-1 integrase on viral fitness. J Acquir Immune Defic Syndr. 2010; 55(2):148-55. PMC: 2943977. DOI: 10.1097/QAI.0b013e3181e9a87a. View

17.

Brenner B, Lowe M, Moisi D, Hardy I, Gagnon S, Charest H . Subtype diversity associated with the development of HIV-1 resistance to integrase inhibitors. J Med Virol. 2011; 83(5):751-9. DOI: 10.1002/jmv.22047. View

18.

Cohen C, Elion R, Ruane P, Shamblaw D, DeJesus E, Rashbaum B . Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection. AIDS. 2011; 25(6):F7-12. DOI: 10.1097/QAD.0b013e328345766f. View

19.

Shafer R . Rationale and uses of a public HIV drug-resistance database. J Infect Dis. 2006; 194 Suppl 1:S51-8. PMC: 2614864. DOI: 10.1086/505356. View

20.

Rangel H, Garzaro D, Fabbro R, Martinez N, Ossenkop J, Torres J . Absence of primary integrase resistance mutations in HIV type 1-infected patients in Venezuela. AIDS Res Hum Retroviruses. 2010; 26(8):923-6. DOI: 10.1089/aid.2010.0039. View